Tag: Boston Scientific

Endologix Announces Exclusive Distributor Agreement with Boston Scientific for the Chinese Market

IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced an agreement naming Boston Scientific Corporation (NYSE: BSX) the exclusive distributor for Endologix products in China. The long-term agreement includes distribution rights to Endologix’s current EndoVascular Aneurysm Repair (EVAR) and Endovascular Aneurysm […]

Boston Scientific Announces Results For Second Quarter 2019

MARLBOROUGH, Mass., July 24, 2019 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated sales of $2.631 billion during the second quarter of 2019. This represents growth of 5.6 percent on a reported basis, 8.0 percent on an operational1 basis and 6.3 percent on an organic2 basis, all compared to the prior year period. The company reported […]

Boston Scientific Presents Strategies for Sustained Long-Range Growth Targets at 2019 Investor Day

MARLBOROUGH, Mass., June 26, 2019 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) is hosting a meeting with the investment community today in New York City to review its business and long-term growth strategies. The company is presenting plans for its product pipeline and strategic investments to enable improved clinical and economic outcomes, sustain category leadership […]

InterVene Raises $15 Million in Series B Funding for First Catheter-Based System to Correct Deep Vein Valve Failure

SOUTH SAN FRANCISCO–(BUSINESS WIRE)–InterVene Inc. today announced it has raised $15 million in a Series B financing round. The company’s BlueLeaf® Endovenous Valve Formation System is the first catheter-based solution for deep vein reflux (DVR) — the failure of venous valves in the legs — that does not require an implant. […]

Boston Scientific Initiates Trial Comparing Left Atrial Appendage Closure to Direct Oral Anticoagulants for Stroke Risk Reduction Post-AFib Ablation

MARLBOROUGH, Mass., May 22, 2019 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) has initiated the OPTION trial to compare safety and effectiveness of the next-generation WATCHMAN FLX™ left atrial appendage closure (LAAC) platform to first-line oral anticoagulants (OAC) – including direct oral anticoagulants (DOAC) and warfarin – for stroke risk reduction in patients with […]

Boston Scientific Receives U.S. FDA Approval for The VICI VENOUS STENT™ System

MARLBOROUGH, Mass., May 6, 2019 /PRNewswire/ — Boston Scientific (NYSE: BSX) announced today that the U.S Food and Drug Administration (FDA) has approved the VICI VENOUS STENT™ System for the treatment of iliofemoral venous obstructive disease, which occurs when the flow of blood through the veins located deep in the pelvic region becomes blocked […]

Boston Scientific Receives FDA Approval for LOTUS Edge™ Aortic Valve System

MARLBOROUGH, Mass., April 23, 2019 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the LOTUS Edge™ Aortic Valve System. Delivered via a minimally-invasive procedure, this transcatheter aortic valve replacement (TAVR) technology is approved for patients with severe aortic stenosis who are considered at […]

Boston Scientific Announces Results For First Quarter 2019

MARLBOROUGH, Mass., April 24, 2019 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated sales of $2.493 billion during the first quarter of 2019. This represents growth of 4.8 percent on a reported basis, 7.8 percent on an operational1 basis and 6.3 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP […]

Boston Scientific Receives CE Mark for Next Generation WATCHMAN FLX™ Left Atrial Appendage Closure Device

MARLBOROUGH, Mass., March 13, 2019 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) announced it has received CE Mark and initiated a limited market release of the next generation WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device in Europe. Patients with AF are five times more likely to suffer a stroke than someone with a normal heart […]

Boston Scientific Announces Scheduled Data at EHRA 2019 Congress

MARLBOROUGH, Mass., March 11, 2019 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced key data that will be featured at EHRA 2019, the annual congress of the European Heart Rhythm Association (EHRA) in Lisbon, Portugal, on March 17-19. Two late-breaking clinical trials will be presented, including: Outcomes from AF-FICIENT I, a prospective, multicenter, single arm […]